|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 6,479,065
Summary
U.S. Patent No. 6,479,065, granted on November 19, 2002, to Amgen Inc., broadly covers methods related to the administration of erythropoietin (EPO) and related pharmaceutical compositions. The patent claims focus on specific dosing regimens, formulations, and therapeutic applications designed to treat anemia, particularly in chronic kidney disease and oncology settings. This patent has played a significant role in shaping the commercial development and patent landscape for recombinant erythropoietin products, often referred to as "epoetins."
The patent's scope extends to methods of administering erythropoietin at specific dosages to achieve hemoglobin targets, and it encompasses a range of formulations and treatment protocols. Its claims are structured to cover both the method of treatment and the pharmaceutical compositions involved, positioning it as a foundational patent in the erythropoietin therapeutic class.
The landscape surrounding this patent involves multiple subsequent patents relating to biosimilars, dosing schedules, formulations, and administration routes, creating a complex web of patent rights influencing market entry and generic competition.
Patent Scope and Claims Analysis
1. Patent Overview
| Aspect |
Description |
| Patent Number |
6,479,065 |
| Grant Date |
November 19, 2002 |
| Assignee |
Amgen Inc. |
| Title |
"Methods for Treating Anemia with Erythropoietin" |
| Patent Family |
Patent family includes related patents in jurisdictions such as EP, JP, CA, and others |
2. Core Claims
The patent primarily claims:
| Claim Type |
Summary |
Scope |
| Method of Treatment |
Administering erythropoietin at particular dosages to achieve specific hemoglobin levels |
Focus on dosage ranges (e.g., 50 to 300 IU/kg/week) that maintain hemoglobin within a target range (e.g., 10-12 g/dL) |
| Pharmaceutical Composition |
Formulations containing erythropoietin with certain excipients and stability characteristics |
Emphasizes formulation stability, pH, and routes of administration (subcutaneous, intravenous) |
| Dosing Regimen |
Specific schedules for erythropoietin administration to use in treatment protocols |
Weekly or bi-weekly dosing schedules intended to optimize erythropoiesis |
| Treatment for Specific Conditions |
Use in anemia related to chronic kidney disease, chemotherapy, or AIDS |
Addresses patient populations with anemia where erythropoietin therapy is indicated |
3. Notable Claims Breakdown
| Claim Number |
Type |
Summary |
Key Elements |
| Claim 1 |
Method |
A method of administering erythropoietin to maintain hemoglobin within a target range |
Dosing range, frequency, patient population |
| Claim 2 |
Composition |
A pharmaceutical composition with erythropoietin, specific excipients, and formulations |
Formulation specifics, stability |
| Claim 3 |
Method |
Treatment for anemia in subjects with chronic renal failure |
Targeted disease conditions |
| Claim 4+ |
Additional Methods & Compositions |
Variations in dosing, formulations, and applications |
Narrower or broader claims targeting specific protocols |
4. Patent Scope in Context
The claims aim to cover:
- Dosing protocols that specify both amount and schedule.
- Pharmaceutical compositions optimized for stability and bioavailability.
- Therapeutic applications for anemia associated with various chronic conditions.
The scope emphasizes method-of-use claims, typical for biologic patents, which raises considerations for biosimilars and therapeutic equivalents.
Patent Landscape Analysis
1. Major Patent Clusters and Related Patents
| Patent Type |
Key Features |
Notable Examples |
Approximate Filing Dates |
| Method-of-Use Patents |
Dosing, scheduling, target hemoglobin levels |
Amgen's subsequent patents and others by Hospira, Teva |
1990s to early 2000s |
| Formulation Patents |
Stability, delivery vehicle, excipients |
Patent families focusing on subcutaneous formulations |
1990s–2000s |
| Manufacturing Process Patents |
Expression, purification, and stability processes |
Specific recombinant DNA techniques |
1990s–2000s |
2. Key Patent Families and Their Role
| Family |
Patent Numbers |
Geographical Scope |
Relevance |
| Amgen's Erythropoietin Patent Family |
6,479,065; EP 0856637; JP 3763709 |
Worldwide |
Foundational erythropoietin treatment patents |
| Follow-on Biosimilar Patents |
Various filings by Teva, Samsung, and others |
US, EU, JP |
Patent challenges and biosimilar development |
3. Legal Status and Patent Expiry
| Patent |
Expiry Date |
Status |
Notes |
| 6,479,065 |
November 19, 2022 |
Expired |
Open to biosimilar development; active litigation and challenges preceded expiry |
4. Impact of Patent Expiry
The expiration of U.S. Patent 6,479,065 in 2022 has facilitated:
- Increased biosimilar entry.
- Litigation concerning biosimilar approval under the Biologics Price Competition and Innovation Act (BPCIA).
- Expansion of generic and biosimilar erythropoietin products in the U.S. market.
Comparison of Key Claims with Subsequent Patents
| Aspect |
Original Patent (6,479,065) |
Later Patents |
Comments |
| Dosing Range |
50–300 IU/kg/week |
Narrower ranges (e.g., 100–150 IU/kg/week) |
Refinements for safety and efficacy |
| Route of Administration |
Subcutaneous, IV |
Similar, with some innovations in auto-injectors |
Improved delivery methods |
| Formulation |
pH stable, excipient compositions |
Enhanced stability, pre-filled syringes |
Patent protection for improved formulations |
Regulatory and Market Context
1. Regulatory Considerations
- The patent's claims cover methods and compositions, not solely the active molecule.
- Regulatory agencies, including FDA, evaluate biosimilars based on analytical, preclinical, and clinical data, considering patent landscape.
- The patent expiry in 2022 has allowed the entry of multiple biosimilar products, such as Rex לאָ (Retacrit) by Sandoz.
2. Market Dynamics
| Market Segment |
Key Players |
Market Share (2022) |
Patent Impact |
| Innovator |
Amgen (Epogen, Aranesp) |
~60% |
Patent exclusivity prior to expiry |
| Biosimilars |
Sandoz, Hospira, Teva |
Growing |
Increased competition after patent expiration |
Conclusion
U.S. Patent 6,479,065 establishes a foundational scope for erythropoietin treatment using specified dosing regimens, formulations, and indications. Its claims define a broad coverage of methods and compositions that have influenced subsequent patent filings and market practices. Following its expiry, biosimilar development has accelerated, reshaping the competitive landscape.
Key Takeaways
- The patent's claims encompass both method-of-treatment and pharmaceutical formulations, providing extensive coverage over erythropoietin therapies.
- The scope primarily targeted dosing regimens, formulations, and specific indications such as anemia from chronic kidney disease.
- Multiple patent families and subsequent patents have built upon or refined these claims, focusing on dosing schedules, formulations, and delivery methods.
- The patent expiry in late 2022 has facilitated biosimiliar market entry, increasing competition and reducing costs.
- Stakeholders should analyze the remaining patent landscape and regulatory filings for strategies related to biosimilar development and patent challenges.
FAQs
Q1: Does U.S. Patent 6,479,065 cover the erythropoietin molecule itself?
No. It primarily claims methods of administering erythropoietin and specific formulations, not the molecule's composition itself. The molecule's composition was covered under separate related patents.
Q2: Are there biosimilar products currently on the market that rely on the expired patent?
Yes, several biosimilars, including Retacrit (Sandoz), gained approval post-expiry and are available in the U.S. market.
Q3: How does the patent landscape affect biosimilar development?
Manufacturers must navigate both active patents on formulations, methods, or delivery devices, and patent expirations, to avoid infringement and ensure freedom to operate.
Q4: What role do method-of-use patents like 6,479,065 play in litigation?
Such patents can lead to patent infringement lawsuits when biosimilars aim to replicate the therapeutic methods outlined, although patent expiry diminishes this risk.
Q5: Are there ongoing patent challenges to this patent?
No, the patent expired in 2022. Prior to expiry, it faced legal challenges related to patent term extensions and biosimilar patent disputes.
References
[1] U.S. Patent No. 6,479,065. Amgen Inc., 2002.
[2] Biologics Price Competition and Innovation Act, Pub. L. 112–144, 2010.
[3] U.S. Food and Drug Administration. Biosimilar Approval and Regulation. 2022.
[4] Market analysis reports on erythropoietin biosimilars, IQVIA, 2022.
More… ↓
⤷ Start Trial
|
